BPTSY (Biophytis) Debt-to-Asset : (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BPTSY Biophytis SA BPTSY
19 GF Score
Price $0.25
! 4 Warning Signs
View Full Analysis

What is Biophytis Debt-to-Asset?

Biophytis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $ Mil. Biophytis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $ Mil. Biophytis's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $ Mil.

Biophytis  (OTCPK:BPTSY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biophytis Debt-to-Asset Related Terms

Biophytis Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Biophytis's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis Debt-to-Asset Chart

Biophytis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.66 0.69 1.43 -

Biophytis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 1.11 1.43 1.17 -

BPTSY vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Biophytis's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biophytis Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biophytis's Debt-to-Asset falls into.


BPTSY
19GF Score
Biophytis SA BPTSY
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biophytis's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) /
=N/A

Biophytis's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a French clinical-stage biotechnology company that develops drug candidates for age-related and respiratory diseases. Its lead candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule that acts on the renin-angiotensin system and is being studied for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy, and respiratory failure associated with conditions such as COVID-19. The company also has earlier-stage programs, including BIO102 and BIO103, targeting degenerative processes linked to aging. Biophytis operates primarily in France, with research and development activities conducted in-house and through partnerships, and it has pursued clinical trials in Europe and other regions. As a clinical-stage company, it has no marketed products and generates no product revenue, relying on equity financing, public grants, and partnership funding to advance its pipeline.
19GF Score

Get the complete analysis for BPTSY

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price